Core Insights - Burcon Nutrascience Corporation has made significant advancements in commercialization, achieving first commercial production and sales of Puratein® C canola protein and FavaPro fava protein in Q2 FY26 [1][7] - The company recorded revenues of $0.36 million in Q2 FY26, representing a 783% increase compared to the same period last year, driven by initial protein sales and contract manufacturing [7] - Burcon received over $500,000 in commercial sales orders after the quarter-end, indicating growing demand as customers transition from evaluations to purchase orders [1][7] Company Developments - The Galesburg facility has successfully initiated commercial production of multiple proteins, including Puratein® C and FavaPro, while scaling Peazazz® C pea protein [1] - The company has strengthened its financing through up to $4.0 million in unsecured convertible debentures and a $0.7 million short-term loan, with at least $2.0 million of insider participation [7] - Operational flexibility allows Burcon to quickly meet evolving customer needs with consistent quality [1]

Core Insights - Burcon Nutrascience Corporation has made significant advancements in its commercialization strategy during Q1 FY26, achieving first commercial production of Peazazz® C pea protein and launching FavaPro fava protein [1][6] - The company entered into a multi-year production agreement worth $6.8 million, which supports its revenue target of $1-3 million for 2025 [1][6] - The Galesburg facility utilizes Burcon's proprietary protein technologies, allowing for scalable production across various plant-based proteins, addressing a total addressable market for pea protein estimated between $215 million to $392 million [1][6] Financial Performance - Revenue for Q1 FY26 increased by 44% year-over-year, reaching $0.34 million [6] - Startup costs associated with the Galesburg facility have impacted margins, with expenses now stabilizing at "new normal" levels [6]